



Leadership Team

Mike Luther, PhD, MBA
Chief Executive Officer

Matt Kostura, PhD
Chief Scientific Officer

Alan Cooper, PhD
Head of Chemistry

Andy Anantha, PhD
Head of CMC

Scientific Advisory Board

Briggs Morrison, MD
CEO, Syndax, Inc.

Mike Patane, PhD
President, Mitobridge/Astellas

Jedd Levine, MD, MBA
EVP, Oncology Partners

Josh Rabinowitz, MD, PhD
Princeton University

Rainer Fuchs, PhD
former CIO Harvard Medical School; Biogen & GSK R&D

George Mulligan, PhD
SVP, Mitobridge/Astellas

Mark Manfredi, PhD
CEO, Kyn Therapeutics

Adrian Schwarzer, MD, PhD
Hannover Medical School

Industry

Pharmaceuticals, Oncology, Cancer metabolism

Financing To date

Seed Funding from Syndicate of Private Investors

Company Founding

August 2015 Delaware LLC

Contact Information

BANTAM PHARMACEUTICAL
646-598-4823
www.bantampharma.com
info@bantampharma.com

Highlights

- Bantam is an oncology focused biotech company developing proprietary first-in-class small molecule therapeutics for high unmet medical needs. The initial focus for development is difficult to treat diffuse large B-cell lymphomas (DLBCL) and certain solid tumors.
- Clinical candidate, BTM-3566 is an orally available small molecule with a novel mechanism of action through modulation of eIF2alpha and the ATF4 pathway.
- Demonstrated Proof-of-Concept with durable tumor regression in B-cell lymphoma xenograft studies as a single agent. No significant adverse safety issues.
- Extensive IP estate with patent protection through 2038.
- FDA IND (Investigational New Drug) Application filing expected end of 4th Quarter 2019.
- Strong leadership team with scientific expertise in oncology drug development.
- **Company is seeking to raise up to \$15M for IND and completion of Phase 1b clinical POC by 2021. Investment will create key inflection points for potential exit.**

BANTAM PHARMACEUTICAL: Orally available small molecule clinical candidate, BTM-3566, and pipeline of proprietary compounds are first-in-class that impact novel cancer metabolism pathway. The mechanism of action is unique and is distinct from known targeted therapeutics (e.g., mTOR inhibitors, histone deacetylase, proteasome, and kinase inhibitors via the modulation of eIF2alpha and the ATF4 pathway. Bantam is targeting cancers with unmet need including refractory lymphoid cancers and certain solid tumors.

MARKET OPPORTUNITY: Successful development and commercialization of Bantam compounds could positively impact the lives of >150,000 patients/year in the US alone and address a large US and global market. Total potential annual market for lymphoma and selected solid tumor therapies are estimated to be >\$10.5 Billion/year.

Bantam Pharmaceutical is now expanding its base of investors and partners as it rapidly advances its pipeline toward clinical proof of concept studies.

EXPERIENCED TEAM: The Bantam leadership team has a proven track record in oncology biopharma drug discovery and development. Bantam’s advisory board is comprised of prominent industry leaders with drug development and executive leadership roles with successful companies spanning start-up through global pharma.

INTELLECTUAL PROPERTY: Bantam owns an intellectual property estate that covers the compounds, chemical space, and their broad clinical utility. Bantam also owns recently filed patent applications that feature additional claims related to mechanism and routes of administration. The IP portfolio will support Bantam’s pipeline and any derivative products through at least 2038.

NEAR TERM MILESTONES AND CLINICAL PLAN: Bantam is rapidly progressing **BTM-3566** into the clinic and is seeking partners and funding to complete IND-enabling activities, manufacturing to support clinical trials, and Ph 1a/1b clinical studies.

Key Milestones for BTM-3566	
Candidate Selection (Completed)	Q1 2018
IND-enabling studies & CMC development	Q1 2019
File IND	Q4 2019
Initiate Phase 1 studies	Q1 2020